Why Philadelphia is Poised to Become a Top Cell and Gene Therapy Cluster

The Discovery Labs King of Prussia PA
Published on :

The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.

Gyroscope Therapeutics, which has operations in King of Prussia, raises $148M

Published on :

Gyroscope Therapeutics, a British gene therapy company that has U.S. operations in King of Prussia, has raised $148 million in venture capital funding.
The five-year-old company has now raised about $265 million over three funding rounds since its inception.
Gyroscope’s Series C financing was led by Forbion’s Growth Opportunities Fund. Other investors are Sofinnova Investments, funds and accounts advised by T. Rowe Price Associates, Tetragon Financial Group Limited, an undisclosed healthcare focused fund, Fosun Pharma, Cambridge Innovation Capital and founding investor Syncona.
The five-year-old company plans to use the proceeds from the stock sale to advance the development of its lead gene therapy candidate, GT005, a potential treatment for geographic atrophy secondary to age-related macular degeneration.

A Unique Talent Pool is Propelling Philly to become a Top Biotech Cluster

Published on :

As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.

5 Questions with Danielle Kalkofen, Quality Control Scientist, Vigene Biosciences

Published on :

Danielle Kalkofen is a molecular cell biologist and biochemist with 15 years of industry and academic experience. In 2015, she turned her focus to biological assay development, leading cross-functional teams to develop, validate, and commercialize new pathogen detection assay products.

Vigene Biosciences Sees Growth Through a Commitment to Gene Therapy and Rare Diseases

Published on :

About a year ago, BioBuzz attended the grand opening of Vigene Biosciences (Vigene) brand new headquarters in Rockville, Maryland. It was a fantastic day for Vigene, the BioHealth Capital Region (BHCR), and for the patients and families of people suffering from cancer and rare genetic diseases.

Cell and Gene Therapy’s Future a Complex Mix of Promise and Pitfalls

Published on :

At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.

Philadelphia’s Talent Pipeline Collaborative Readies Region For Cell And Gene Therapy Job Growth –

Published on :

The following op-ed, originally posted on CellandGene.com, was written by CEO Council Executive Director Claire Greenwood and Patricia Day, Manager, Leadership Engagement, Chamber of Commerce for Greater Philadelphia.  On the heels of a 2020 study predicting substantial job growth in the cell and gene therapy sector in Greater Philadelphia, industry leaders in our

In Conversation with Kevin Hannigan, President of Lab Owl®/Automated Control Concepts, Inc.

Published on :

Personalized and regenerative medicines are promising but they are complex to develop and require highly-flexible advanced manufacturing techniques that are still too manually intensive and costly.

5 Questions with Kurt Elam, Senior Director, Sales & Marketing for LabOwl

Published on :

Kurt Elam joined ACC/Lab Owl in 2017 with 20+ years of specialty biopharmaceutical experience, focused primarily on oncology, infectious disease, and critical care/ICU medicine. He has overseen and managed the successful launch of over 16 new FDA approved products/compounds or new indications, and worked to gain formulary approval in managed care organizations, thereby improving access for patients.